AbbVie is giving up its patents on a combination drug that is being studied as a coronavirus treatment, becoming the first major drugmaker to drop its rights to make money from a drug that might be used during the pandemic.
艾伯维(AbbVie)将要放弃一种正被研究用于治疗新型冠状病毒的复合药物的专利，成为首家对一种本来有望在大流行病期间畅销的药物放弃权益的大型制药商。
您已阅读8%（297字），剩余92%（3381字）包含更多重要信息，订阅以继续探索完整内容，并享受更多专属服务。